Clinical Trials Logo

Clinical Trial Summary

After single, yearly, mass treatment of communities with azithromycin for active trachoma, what is the added effectiveness for reduction of trachoma and ocular C. trachomatis infection at one, two, and three years, relative to the added costs, of community-based surveillance and treatment of cases of severe trachoma (TI) semi-annually or every 4 months?


Clinical Trial Description

An important component of a trachoma control program is the effective use of antibiotics, particularly azithromycin, to reduce the pool of chlamydial ocular infection in the communities. A reduction in the pool of infection will reduce the likelihood of transmission and, coupled with effective hygiene and environmental changes, theoretically lead to reduction in disease to the point where active trachoma is no longer a public health problem. Our previous experience with the use of azithromycin for community treatment has shown that even with high rates of coverage, hyperendemic communities will start to experience re-emergent trachoma following treatment by one year. Therefore, it is urgent to determine if there is another treatment strategy for these villages to keep the pool of infection low, and eventually eliminated.A combination approach consisting of mass treatment at yearly intervals and surveillance with a targeted treatment approach in the interim period may be effective in maintaining the low rate of re-emergent disease.We propose to test the cost-effectiveness of three alternative strategies for the frequency of provision of azithromycin, in the context of the Tanzanian National Trachoma Control Program. The strategies have been developed to build on the epidemiological knowledge of trachoma in this area, to be locally appropriate in terms of feasibility and personnel, and to be consistent with the goal of enhancing community control of the program.

A total of nine villages in the Kongwa district of Tanzania will be randomized to one of three groups (a total of three villages per group). The nine villages, with active trachoma rates in pre-school children of 50% or greater, would be slated for enrollment in the National Program, but not currently receiving treatment. Surveys for active trachoma status would be carried out in 300 randomly selected, children ages 1-7 years (pre-school)in each village at baseline, at 6 months post mass treatment, and at one, two, and three years post baseline. The following treatment strategies will be used:

Control villages: Usual practice: The three villages randomized to this arm would receive mass treatment of the community once a year as part of the Tanzania National Trachoma Control program.

Intervention 1. Usual practice plus community surveillance for TI cases and treatment at 6 months: The three villages randomized to this arm would receive mass treatment, similar to the usual practice arm, but in addition, would have a cadre of community volunteers, trained to recognize TI. They will screen their neighborhoods, examining all pre-school children and mothers, and arrange with the health worker for another round of treatment for TI cases and their families at 6 months, and 18 months post baseline.

Intervention 2: Usual practice plus community surveillance for TI cases and treatment every 4 months: The three villages randomized to this arm would have an approach identical to intervention 1, but with surveillance and treatment of TI cases at 4 and 8 months instead of at 6 months.For the second year, they would have surveillance and treatment at 6 months.

Cost data on the community surveillance and treatment program will be collected throughout the first year. Analyses will focus on the additional benefit on reduction in prevalence of trachoma, and ocular C. trachomatis infection, at one, two, and three years of the two alternative strategies, relative to yearly mass treatment alone, and the cost-effectiveness of the three strategies. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00347607
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase Phase 4
Start date April 2002
Completion date November 2005

See also
  Status Clinical Trial Phase
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT01949454 - Fluorometholone as Ancillary Therapy for TT Surgery N/A
Completed NCT01202331 - Tripartite International Research for the Elimination of Trachoma Phase 4
Completed NCT05634759 - Enhancing the A in SAFE for Trachoma Phase 4
Recruiting NCT04185402 - Azithromycin Reduction to Reach Elimination of Trachoma Phase 4
Active, not recruiting NCT00886015 - Modified Instrumentation for Surgery to Correct Trichiasis Phase 3
Completed NCT00792922 - Partnership for Rapid Elimination of Trachoma Phase 4
Completed NCT00522860 - A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Phase 4
Completed NCT00221364 - Trachoma Elimination Follow-up Phase 4
Completed NCT00322972 - Trachoma Amelioration in Northern Amhara (TANA) Phase 4
Withdrawn NCT00286026 - Azithromycin in Control of Trachoma II Phase 4
Completed NCT00347763 - Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Phase 4
Terminated NCT03997487 - Smartphone App for Taking Images of Conjunctivae N/A
Terminated NCT04002726 - App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders N/A
Not yet recruiting NCT06289647 - Azithromycin Reduction to Reach Elimination of Trachoma B Phase 4
Withdrawn NCT02655432 - Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Phase 0
Completed NCT01767506 - A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial N/A
Completed NCT00618449 - Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Phase 4
Completed NCT00356720 - Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Phase 3
Completed NCT03813069 - Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Phase 2